Serevent, Foradil, Advair and Symbicor Warnings
Last week the Food and Drug Administration (FDA) announced that there will be changes in how long-acting beta agonists (LABAs) will be used in the treatment of asthma. This move is aimed to lower the risks of aggravation that may lead to hospitalization or even death.
LABAs are used to treat both asthma and chronic obstructive pulmonary disease (COPD). The studies that the FDA has reviewed involved patients who have been using LABAs to help treat asthma not COPD.
LABAs relax the muscles in bronchial passages, which allow more air to flow. This provides a quick relief for asthma sufferers but it doesn’t address the underlying swelling. The use of LABAs creates the risk of life threatening conditions.
FDA Warning for Brand name asthma Drugs
The FDA said that patients should use products containing only corticosteroids or other asthma-relieving medication whenever possible. But patients who can’t control asthma symptoms in any other way should use LABAs for the shortest possible time but the drug should never be used alone to treat just asthma in adults or children. The risks are most common in children but the FDA also warns adults.
The drugs that are affected by the FDA action that include the LABA products are Serevent, Foradil, Advair and Symbicor that contain both LABAs and inhaled corticosteroids.
Manufactures are going to be required to put new warnings on drug labels to educate patients and physicians about the risks associated with the use of LABA and study weather using the compounds in tandem with other drugs make them safer. The goal is not to eliminate LABAs but to keep them available for patients who really need them because alternative options are not that great.
List of Asthma Drugs that come under the FDA warning: